Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neuro-oncology · Leptomeningeal Disease from Melanoma

Navigating the Diagnostic Process

At a Glance

Leptomeningeal disease from melanoma is diagnosed by combining contrast-enhanced MRI of the brain and entire spine with cerebrospinal fluid testing. A negative MRI or first lumbar puncture does not always exclude disease, so repeat sampling or advanced tests may be needed.

Confirming a diagnosis of leptomeningeal disease (LMD) is often a multi-step process. Because melanoma cells can be sparse within the cerebrospinal fluid (CSF), a single test often isn’t enough to provide a clear answer. Doctors use a combination of advanced imaging and fluid analysis to build a complete picture of your neuraxis—the entire highway of the brain and spinal cord [1]. LMD is often diagnosed as “confirmed” or “probable” based on how these pieces fit together.

The Need for Complete Neuraxis Imaging

When LMD is suspected, a contrast-enhanced MRI is the first major step. It is crucial that this scan covers both the brain and the entire spine [2].

  • Why the entire spine? Even if your symptoms are only in your head, the disease may have already affected the lower spinal area or the cauda equina (nerve roots at the base of the spine) [3]. Imaging only the brain might miss significant disease [1].
  • The Role of Contrast: A special dye (gadolinium) is injected into an IV. Rather than making cancer cells “glow,” the contrast highlights areas where the blood-brain barrier is leaking. This abnormal leakage (called “enhancement”) can show up as a linear or nodular coating on the brain or nerves [4]. However, this enhancement is not perfect—infection or severe inflammation can sometimes mimic these signs.
  • Limitations: A “clear” or negative MRI does not rule out LMD. In many cases, the cancer cells are present in the fluid but haven’t yet formed a large enough disruption to be seen on a scan [5].

The “Gold Standard”: CSF Cytology

The most definitive way to diagnose LMD is a lumbar puncture (spinal tap). A doctor inserts a needle into the lower back to collect a sample of CSF, which is then sent to a lab for cytology—where specialists look at the fluid under a microscope to find actual melanoma cells [1][4].

Safety First: A lumbar puncture cannot be done blindly. Your team must review your brain and spine MRI and assess your clinical symptoms before the procedure. If you have significant pressure buildup (mass effect) or obstructive hydrocephalus, a lumbar puncture can be dangerous and cause the brain to shift (herniation). The treating team will determine if it is safe to proceed. During the procedure, they may also measure your “opening pressure” to check for hypertension in the fluid.

While cytology provides visual proof of cancer, it has a significant hurdle: low sensitivity.

  • The “Hide and Seek” Problem: On the first lumbar puncture, the test only catches the cancer cells about 50% to 67% of the time [6][7].
  • The Power of Repetition: If your first test is negative but your symptoms or MRI strongly suggest LMD, your doctor may recommend a second procedure to collect a larger volume of fluid, significantly increasing the chances of an accurate diagnosis [6][8].

Advanced “Liquid Biopsy” Tests

Because cytology can miss the cancer cells, doctors are increasingly using advanced techniques to find microscopic traces of the tumor. These tests may not be available at every local clinic.

CSF Cell-Free DNA (cfDNA)

Melanoma cells shed tiny fragments of their genetic material (DNA) into the CSF. Scientists can test the fluid for specific mutations common in melanoma, such as BRAF V600 or NRAS Q61 [9].

  • Increased Accuracy: In some studies, cfDNA testing detected the mutation in about 30% of samples where standard cytology was negative or inconclusive [10].
  • A Word of Caution: If you have a large melanoma brain metastasis that is abutting the fluid spaces, it might shed DNA into the fluid even without widespread LMD. Your doctor will interpret these results alongside your MRI [11].

Circulating Tumor Cells (CTCs)

Newer assays, such as CNSide, use advanced technology to capture and count individual melanoma cells (CTCs) in the fluid [12].

  • Sensitivity: These tests can be highly sensitive and can help quantify the disease burden [13].
  • Monitoring: Because these tests provide a specific cell count, they may be used to track whether your treatment is working over time [14][15].

By combining these tools—MRI, clinical exams, cytology, and genetic testing—your care team can build the most accurate diagnosis possible.

Common questions in this guide

What tests are used to diagnose leptomeningeal disease from melanoma?
Doctors usually combine contrast-enhanced MRI of the brain and entire spine with a lumbar puncture and cerebrospinal fluid cytology. If the results are unclear, testing for tumor DNA or circulating tumor cells may provide additional information.
Can a normal MRI rule out leptomeningeal disease?
No. Melanoma cells may be present in the cerebrospinal fluid before they cause changes that can be seen on an MRI, so doctors consider the scan together with symptoms and fluid test results.
What does a negative first lumbar puncture mean?
A negative first cerebrospinal fluid cytology test does not always rule out leptomeningeal disease because the sample may not contain detectable melanoma cells. If symptoms or imaging remain concerning, a repeat lumbar puncture with a larger fluid sample may improve the chance of detection.
Is a lumbar puncture safe when leptomeningeal disease is suspected?
Safety depends on the brain and spine MRI and on whether there are signs of increased pressure, mass effect, or obstructed fluid flow. A lumbar puncture can be dangerous in some of these situations, so the treating team must decide whether it is safe before the procedure.
What are CSF cell-free DNA and circulating tumor cell tests?
Cell-free DNA testing looks for melanoma-related genetic changes in cerebrospinal fluid, while circulating tumor cell tests look for individual cancer cells. These tests may add information when cytology is inconclusive and may help monitor disease, but nearby brain metastases can affect how some results are interpreted.

Get notified when new evidence is published on leptomeningeal melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Leptomeningeal metastases: a RANO proposal for response criteria.

    Chamberlain M, Junck L, Brandsma D, et al.

    Neuro-oncology 2017; (19(4)):484-492 doi:10.1093/neuonc/now183.

    PMID: 28039364
  2. 2

    Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors.

    Chowdhary S, Damlo S, Chamberlain MC

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):S1-S16 doi:10.1177/107327481702400118.

    PMID: 28557973
  3. 3

    Therapy of leptomeningeal metastasis in solid tumors.

    Mack F, Baumert BG, Schäfer N, et al.

    Cancer treatment reviews 2016; (43()):83-91.

    PMID: 26827696
  4. 4

    Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

    Piña Y, Yadugiri S, Yeboa DN, et al.

    Current oncology reports 2022; (24(1)):43-54 doi:10.1007/s11912-021-01162-3.

    PMID: 35059999
  5. 5

    Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis.

    Nakasu Y, Deguchi S, Nakasu S, et al.

    Neuro-oncology advances 2023; (5(1)):vdad002 doi:10.1093/noajnl/vdad002.

    PMID: 36968290
  6. 6

    Leptomeningeal Carcinomatosis: A Call for Optimizing Diagnostic Sensitivity by the Hematology Laboratory.

    Lardinois B, Miller L, Randazzo A, et al.

    Case reports in oncology 2021; (14(2)):1248-1253 doi:10.1159/000518314.

    PMID: 34703443
  7. 7

    Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment.

    Zhang R, Zhao Q, Cao Y, et al.

    Lung cancer (Amsterdam, Netherlands) 2026; (222()):109667 doi:10.1016/j.lungcan.2026.109667.

    PMID: 42893629
  8. 8

    Leptomeningeal carcinomatosis as primary manifestation of pancreatic cancer.

    Trinh VT, Medina-Flores R, Chohan MO

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (30()):124-127 doi:10.1016/j.jocn.2015.12.027.

    PMID: 26972704
  9. 9

    Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series.

    Dirven I, Vounckx M, Kessels JI, et al.

    Pigment cell & melanoma research 2024; (37(6)):822-830 doi:10.1111/pcmr.13186.

    PMID: 38990845
  10. 10

    Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.

    Ballester LY, Glitza Oliva IC, Douse DY, et al.

    Journal of neuropathology and experimental neurology 2018; (77(7)):628-635 doi:10.1093/jnen/nly046.

    PMID: 29873738
  11. 11

    Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.

    White MD, Klein RH, Shaw B, et al.

    JAMA network open 2021; (4(8)):e2120040 doi:10.1001/jamanetworkopen.2021.20040.

    PMID: 34369989
  12. 12

    Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal disease.

    Onoichenco A, Galvez R, Schultz A, et al.

    Neuro-oncology advances 2026; (8(1)):vdag046 doi:10.1093/noajnl/vdag046.

    PMID: 41924095
  13. 13

    Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

    Lin X, Fleisher M, Rosenblum M, et al.

    Neuro-oncology 2017; (19(9)):1248-1254 doi:10.1093/neuonc/nox066.

    PMID: 28821205
  14. 14

    Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.

    Barbour AB, Blouw B, Taylor LP, et al.

    Journal of neuro-oncology 2024; (167(3)):509-514 doi:10.1007/s11060-024-04615-4.

    PMID: 38441840
  15. 15

    Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSideTM.

    Puri S, Malani R, Chalmers A, et al.

    Neuro-oncology advances 2024; (6(1)):vdad150 doi:10.1093/noajnl/vdad150.

    PMID: 38196737

This page explains diagnostic testing for leptomeningeal disease from melanoma for informational purposes only and does not constitute medical advice. Your oncology and neurology teams should interpret your MRI and CSF results and decide whether a lumbar puncture is safe for you.